Jeffrey Garland
Internal Medicine · Woodlawn, VANPI 1306878756
Payments from drug & device makers
Across 10 payments — averaging $347.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$3K
- Acadia Pharmaceuticals Inc$165
- Cardinal Health 200 LLC$114
- Sunovion Pharmaceuticals Inc.$41
- Novo Nordisk$20
What the payments were for
- Travel & lodging$3,13290%
- Food & beverage$34010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 1 | $3,132 |
| Acadia Pharmaceuticals Inc | 5 | $165 |
| Cardinal Health 200 LLC | 2 | $114 |
| Sunovion Pharmaceuticals Inc. | 1 | $41 |
| Novo Nordisk | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPOVIO$3,132
How this compares
$3,472 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 36 | $87,237 |
| EliquisApixaban | 83 | $53,241 |
| XareltoRivaroxaban | 39 | $22,570 |
| TrulicityDulaglutide | 20 | $21,000 |
| JardianceEmpagliflozin | 24 | $17,433 |
| LinzessLinaclotide | 21 | $14,052 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,001 |
| MyrbetriqMirabegron | 22 | $10,410 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,499 |
| Famotidine | 116 | $5,554 |
| Paliperidone ErPaliperidone | 12 | $4,621 |
| Divalproex Sodium | 72 | $4,153 |
| Memantine Hcl | 176 | $4,036 |
| Omeprazole | 221 | $3,265 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 85 | $2,548 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Woodlawn
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.